Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - ScienceDirect
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
Frontiers | Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study - The Lancet Regional Health – Western
Efficacy of TAGRISSO® (osimertinib) in Resectable EGFRm NSCLC
AstraZeneca's TAGRISSO® (osimertinib) shows potential as a new standard of care in 1st-line EGFR-mutated non-small cell lung cancer at ESMO 2017 Congress
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Scientific Reports
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Osimertinib Shows No OS Benefit Versus Chemotherapy in EGFR T790M-Mutant Advanced NSCLC Study
Why is Tagrisso not reimbursable as 1st-line treatment in Korea? < Hospital < Article - KBR
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
